This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Lipids and Lipid Disorders  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: In response to Dr Taylor and Dr Blakely, the ALLHAT investigators believe that our data provide no independent evidence that statin treatment is beneficial in older, hypertensive, moderately hypercholesterolemic patients, but that a number of other similarly large, long-term statin trials reported over the past 9 years do provide very persuasive evidence of reductions in mortality as well as CHD event rates. While population-specific explanations (the inclusion of large numbers of elderly patients, women, those with hypertension, etc) may explain our results when considered by themselves, they cannot be reconciled with the positive results of other large statin trials, which also included such patients but were blinded and attained more substantial cholesterol differentials between treated and control patients. Like Blakely, we therefore concluded that the most likely explanation for the apparent disparity in the results of ALLHAT-LLT and otherwise comparable placebo-controlled statin trials is the far smaller cholesterol . . . [Full Text of this Article]

RELATED ARTICLES

Lipid-Lowering Therapy and Risk of Coronary Events
William C. Taylor
JAMA. 2003;289(16):2070.
EXTRACT | FULL TEXT  

Lipid-Lowering Therapy and Risk of Coronary Events
John A. Blakely
JAMA. 2003;289(16):2070-2071.
EXTRACT | FULL TEXT  

Lipid-Lowering Therapy and Risk of Coronary Events
Luca Mascitelli and Francesca Pezzetta
JAMA. 2003;289(16):2071.
EXTRACT | FULL TEXT  

Lipid-Lowering Therapy and Risk of Coronary Events
Claude K. Lardinois
JAMA. 2003;289(16):2071.
EXTRACT | FULL TEXT